Literature DB >> 28039523

High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer's disease: the FINRISK Study.

Juho Tynkkynen1,2, Jussi A Hernesniemi3, Tiina Laatikainen4,5,6, Aki S Havulinna4, Perttu Salo4, Stefan Blankenberg7,8, Tanja Zeller7,8, Veikko Salomaa4.   

Abstract

Cardiac troponin and N-terminal pro-brain natriuretic peptide (NT-proBNP) are known to associate with incident dementia. The purpose of our study was to examine whether high-sensitivity cardiac troponin I (hs-TnI) and NT-proBNP are associated with incident dementia and Alzheimer's disease (AD) independently of each other. Our study was a part of the national population-based health examination survey, FINRISK 1997, with a total sample of 7114 subjects, including 407 incident dementia cases and 319 AD cases during the follow-up time of 18 years. Using multivariate Cox regression analyses, we calculated the hazard ratios (HR) for hs-TnI and NT-proBNP. Analyses were adjusted for the previously known dementia/AD risk factors, including the apoE genotype. NT-proBNP was independently associated with incident dementia (HR 1.32, 95% CI 1.17-1.49) and AD (HR 1.30, 95% CI 1.13-1.5). Hs-TnI was also associated with incident dementia (HR 1.12, 95% CI 1.02-1.23), but not independent of NT-proBNP (HR 1.10, 95% CI 0.99-1.21). Hs-TnI was not associated with incident AD. The results remained similar in cause-specific Cox regression models and among subjects over 40 years of age. NT-proBNP and hs-TnI improved the reclassification of dementia risk in 10 years follow-up, and hs-TNI also in 18 years of follow-up. Neither hs-TnI nor NT-proBNP was able to outperform each other in risk reclassification of dementia. Both cardiovascular biomarkers, NT-proBNP and hs-TnI, were associated with incident dementia independently of traditional dementia risk factors including the apoE genotype. NT-proBNP was also associated with AD. Both markers offered a better dementia risk reclassification compared with traditional risk factors.

Entities:  

Keywords:  Alzheimer’s disease; Apo E genotype; Cardiac troponin I; Dementia; NT-proBNP; Population based; Prospective

Mesh:

Substances:

Year:  2016        PMID: 28039523     DOI: 10.1007/s00415-016-8378-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study.

Authors:  Andrea L C Schneider; Andreea M Rawlings; A Richey Sharrett; Alvaro Alonso; Thomas H Mosley; Ron C Hoogeveen; Christie M Ballantyne; Rebecca F Gottesman; Elizabeth Selvin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

2.  Serum cholesterol and risk of Alzheimer disease: a community-based cohort study.

Authors:  G Li; J B Shofer; W A Kukull; E R Peskind; D W Tsuang; J C S Breitner; W McCormick; J D Bowen; L Teri; G D Schellenberg; E B Larson
Journal:  Neurology       Date:  2005-10-11       Impact factor: 9.910

3.  Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk scores.

Authors:  Sara Kaffashian; Aline Dugravot; Alexis Elbaz; Martin J Shipley; Séverine Sabia; Mika Kivimäki; Archana Singh-Manoux
Journal:  Neurology       Date:  2013-04-02       Impact factor: 9.910

4.  Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study.

Authors:  A Solomon; I Kåreholt; T Ngandu; B Winblad; A Nissinen; J Tuomilehto; H Soininen; M Kivipelto
Journal:  Neurology       Date:  2007-03-06       Impact factor: 9.910

5.  High total cholesterol levels in late life associated with a reduced risk of dementia.

Authors:  M M Mielke; P P Zandi; M Sjögren; D Gustafson; S Ostling; B Steen; I Skoog
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

6.  Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. The WHO MONICA Project.

Authors: 
Journal:  World Health Stat Q       Date:  1988

7.  Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Lori B Daniels; Paul Clopton; Christopher R deFilippi; Otto A Sanchez; Hossein Bahrami; Joao A C Lima; Russell P Tracy; David Siscovick; Alain G Bertoni; Philip Greenland; Mary Cushman; Alan S Maisel; Michael H Criqui
Journal:  Am Heart J       Date:  2015-09-28       Impact factor: 4.749

8.  Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.

Authors:  Stefan Blankenberg; Tanja Zeller; Olli Saarela; Aki S Havulinna; Frank Kee; Hugh Tunstall-Pedoe; Kari Kuulasmaa; John Yarnell; Renate B Schnabel; Philipp S Wild; Thomas F Münzel; Karl J Lackner; Laurence Tiret; Alun Evans; Veikko Salomaa
Journal:  Circulation       Date:  2010-05-24       Impact factor: 29.690

9.  What have we learnt about high-density lipoprotein cholesterol measurements during 32 years? Experiences in Finland 1980-2012.

Authors:  Jaana Leiviskä; Jouko Sundvall; Georg Alfthan; Riitta Tähtelä; Veikko Salomaa; Matti Jauhiainen; Erkki Vartiainen
Journal:  Clin Chim Acta       Date:  2012-10-18       Impact factor: 3.786

10.  Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  Insa Feinkohl; Marketa Keller; Christine M Robertson; Joanne R Morling; Rachel M Williamson; Lisa D Nee; Stela McLachlan; Naveed Sattar; Paul Welsh; Rebecca M Reynolds; Tom C Russ; Ian J Deary; Mark W J Strachan; Jackie F Price
Journal:  Diabetes Care       Date:  2013-04-11       Impact factor: 19.112

View more
  5 in total

1.  High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change.

Authors:  Yashashwi Pokharel; Farah Mouhanna; Andrea L C Schneider; Andreea M Rawlings; David S Knopman; Vijay Nambi; Salim S Virani; Ron C Hoogeveen; Alvaro Alonso; Gerardo Heiss; Josef Coresh; Thomas Mosley; Rebecca Gottesman; Elizabeth Selvin; Christie Ballantyne; Melinda C Power
Journal:  J Am Geriatr Soc       Date:  2019-07-30       Impact factor: 5.562

Review 2.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

Review 3.  Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Authors:  Owen Sanders; Lekshmy Rajagopal
Journal:  J Alzheimers Dis Rep       Date:  2020-06-16

4.  N-Terminal pro-Brain Natriuretic Peptide and Associations With Brain Magnetic Resonance Imaging (MRI) Features in Middle Age: The CARDIA Brain MRI Study.

Authors:  Ian T Ferguson; Martine Elbejjani; Behnam Sabayan; David R Jacobs; Osorio Meirelles; Otto A Sanchez; Russell Tracy; Nick Bryan; Lenore J Launer
Journal:  Front Neurol       Date:  2018-05-07       Impact factor: 4.003

5.  Artificial Intelligence-Assisted Identification of Genetic Factors Predisposing High-Risk Individuals to Asymptomatic Heart Failure.

Authors:  Ning-I Yang; Chi-Hsiao Yeh; Tsung-Hsien Tsai; Yi-Ju Chou; Paul Wei-Che Hsu; Chun-Hsien Li; Yun-Hsuan Chan; Li-Tang Kuo; Chun-Tai Mao; Yu-Chiau Shyu; Ming-Jui Hung; Chi-Chun Lai; Huey-Kang Sytwu; Ting-Fen Tsai
Journal:  Cells       Date:  2021-09-15       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.